Zusammenfassung

Hormone Research (2000) 53:185Ð192

Growth Hormone Normalises Height, Prediction of Final Height and Hand Length in Children with Prader-Willi Syndrome after 4 Years of Therapy
U. Eiholzer, D. l'Allemand Abstract

BACKGROUND:
Based on the reported favourable effects of growth hormone (GH) treatment on growth and body composition in Prader-Labhart-Willi syndrome, we studied age dependency and the longterm effects on growth dynamics to elucidate the assumed hypothalamic GH deficiency.

METHODS:
We examined 23 children treated with hGH (24 U/m 2 /week) during a median of 4 (range 1.5-5.5) years; group 1: 10 young underweight (age 0.3- 4.1 years), group 2: 8 prepubertal overweight (age 3.7-9.5 years) and group 3: 5 pubertal overweight children (age 9.0-14.6 years).

RESULTS:
After 4 years of therapy, height gain amounted to 1.8 SD; height (0.0 SD) and hand length (-0.2 SD) were normalised in the 2 prepubertal groups; in children above 6 years, height prediction approached parental target height. Weight for height rose in group 1 (to 0.64 SD) and decreased in group 2 (to 0.71 SD) to normal levels. Bone maturation of the pubertal children was too advanced to show a clear growth response to GH (height gain 0.42 SD). Even in this group, weight for height was reduced, but remained supernormal.

CONCLUSION:
Under exogenous GH, growth and body proportions are normalised in prepubertal children. With early institution of treatment, final height prediction reaches the parental target height range after 3 years. Such a growthpromoting effect of exogenous GH has so far only been described in children with GH deficiency.